The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors.
 
Jiayu Wang
No Relationships to Disclose
 
Wenna Wang
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Yehui Shi
No Relationships to Disclose
 
Yanxia Shi
No Relationships to Disclose
 
Qiufan Zheng
No Relationships to Disclose
 
Shunjiang Yu
Employment - Shanghai Pharmaceuticals Holding Co., Ltd., China
 
Yuanyuan Cao
Employment - Shanghai Pharmaceuticals Holding Co., Ltd, China
 
Ning Xie
Employment - Shanghai Pharmaceuticals Holding Co., Ltd, China
 
Jianru Fan
Employment - Shanghai Pharmaceuticals Holding Co., Ltd, China
 
Binghe Xu
No Relationships to Disclose